Search Results

Containing any of the words

Only of the type

"Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients " Drug Clinical Trial

Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia Drug Clinical Trial

Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. Drug Clinical Trial

Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. Drug Clinical Trial

Re-EValuating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill Drug Clinical Trial

RELATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SYMPTOMATIC SICKLE CELL DISEASE: A PROSPECTIVE STUDY Drug Clinical Trial

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer Drug Clinical Trial

Safety and Feasibility of CD19 Chimeric Antigen Receptor (CAR) T Cells In Adults with CD19 Positive Relapsed and Refractory Acute Lymphoblastic Leukemia or Lymphoma Drug Clinical Trial

Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer Drug Clinical Trial

Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer Drug Clinical Trial